Key result
Prescribing of secondary prevention drugs for IHD increased markedly from 1994 to 2005, with 80% of men and 70% of women receiving a statin by 2005, though combination therapy remained underutilized.
Why the study?
What are the trends in the use of individual and combination secondary prevention medications for ischaemic heart disease in the UK between 1994 and 2005?
Observational (n=51,000)
Yes
What are the trends in the use of individual and combination secondary prevention medications for ischaemic heart disease in the UK between 1994 and 2005?
Despite significant increases in the prescribing of secondary prevention medications for ischaemic heart disease in the UK between 1994 and 2005, substantial opportunities remain to improve the use of combination therapy, particularly in older patients and those without prior MI.
No takes yet. Share an insight, caveat, or question.
High statin uptake bolsters secondary prevention in IHD; extends temporal trends but leaves combination therapy gaps unaddressed.
DeWilde et al. (2007) conducted an observational in ischaemic heart disease (n=51,000). Secondary prevention medications (statins, antiplatelets, beta-blockers, ACE inhibitors) was evaluated on Percentage of subjects with IHD receiving individual drugs and combined treatment in any given year. Prescribing of secondary prevention drugs for IHD increased markedly from 1994 to 2005, with 80% of men and 70% of women receiving a statin by 2005, though combination therapy remained underutilized.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: